Two studies of Mitra Clip System (Abbott Vascular) for Mitral Regurgitation published

Two European studies of Mitra Clip therapy, from Abbott Vascular for the treatment of Mitral Regurgitation (MR) have been published. Results from ACCESS-EU, a European prospective study that enrolled 567 patients at 14 sites, have been published in the Journal of the American College of Cardiology. In addition, findings of the TRAMI registry, which enrolled 1,064 patients at 20 German sites, were recently published in EuroIntervention. Data from ACCESS-EU ahows that in predominantly high surgical risk, elderly patients, the MitraClip procedure demonstrated low rates of hospital mortality and adverse events and provided significant improvements in day-to-day quality of life at one year following treatment. The implant success rate of 99.6 percent.

Results of the TRAMI registry showed similar benefits for the MitraClip therapy in both elderly and younger patients. Hospital mortality was 2.9 percent in elderly patients and 2.8 percent in younger patients (p=0.96). Major adverse car�diovascular or cerebrovascular events (MACCE), defined as a com�posite endpoint of death, myocardial infarction or stroke, was 3.5 percent vs. 3.4 percent (p=0.93) respectively. The majority of patients � 81.8 percent of elderly patients and 86.2 percent of younger patients (p=0.06) � fully recovered.

See: J Am Coll Cardiol. 2013; 61(10_S). doi:10.1016/S0735-1097(13)61752-0 and EuroIntervention 2013;9:84-90 Volume 9 Number 1, May 2013.